Bajaj healthcare has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory documentation with both BSE and NSE on April 07, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Filing

The compliance certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to confirm proper handling of securities received from depository participants for dematerialization during each quarter.

Certificate Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the company's registrar and transfer agent. The firm issued the compliance certificate on April 3, 2026, confirming several key regulatory requirements were met during Q4FY26.

The certificate confirms that:

• Securities received from depository participants for dematerialization were properly accepted or rejected
• All securities were listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within prescribed timelines

Corporate Governance

Monica Tanwar, serving as Company Secretary and Compliance Officer, digitally signed and submitted the compliance documentation. The filing demonstrates Bajaj Healthcare's adherence to corporate governance standards and regulatory requirements for listed companies.

This quarterly compliance filing represents standard regulatory practice for listed companies, ensuring transparency in securities handling and maintaining investor confidence through proper documentation and timely submissions to stock exchanges.

Bajaj Healthcare Limited has disclosed the conversion of convertible warrants into equity shares by a promoter group member under SEBI regulations. Anil Champalal Jain, Managing Director and member of the promoter group, converted 4,55,074 convertible warrants into equity shares on March 18, 2026.

Warrant Conversion Details

The conversion represents a strategic move by the promoter group to increase their equity participation in the company. The disclosure was filed under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as required for substantial acquisitions.

Impact on Share Capital Structure

The warrant conversion has resulted in an expansion of the company's equity base. The total number of equity shares increased significantly following the allotment of new shares to the promoter group member.

Regulatory Compliance

The transaction was completed through the allotment of equity shares pursuant to the conversion of convertible warrants. Anil Champalal Jain's total holding, including the converted shares, now stands at 19,36,544 equity shares, representing 5.75% of the company's total voting capital.

The disclosure indicates that no shares were held under encumbrance categories such as pledge, lien, or non-disposal undertaking. The conversion was processed on March 18, 2026, with the regulatory filing submitted on March 20, 2026.

Market Presence

Bajaj Healthcare Limited's shares are listed on both BSE Limited and National Stock Exchange of India Limited. The company operates under BSE Scrip Code 539872 and NSE Symbol BAJAJHCARE, providing investors with trading access across both major Indian stock exchanges.